ADAMTS 是一类锌依赖的分泌型金属蛋白酶,主要参与细胞外基质 (ECM) 降解与重塑、血液凝固调节、心血管稳态等生理过程。该家族包含 19 种 ADAMTS 蛋白酶 和 7 种 ADAMTS-like 蛋白,其中 ADAMTS1、4、5 负责降解蛋白聚糖,ADAMTS2、3、14 促进前胶原加工,ADAMTS13 通过降解 vWF 参与凝血调节,而 ADAMTS7、12 影响血管平滑肌细胞迁移,与动脉粥样硬化相关。此外,ADAMTS1 和 ADAMTS8 具有肿瘤抑制作用,可通过抑制血管生成限制肿瘤生长。
ADAMTS 的功能异常与多种疾病相关。例如,ADAMTS2 突变会导致 Ehlers-Danlos 综合征 (皮肤松弛症),影响胶原成熟;ADAMTS5 过度活化则会破坏软骨蛋白聚糖,加剧骨关节炎 进程;ADAMTS13 缺陷可引发 血栓性血小板减少性紫癜 (TTP),导致异常血栓形成。此外,ADAMTS7 促进血管病变,推动动脉粥样硬化进展。因此,针对 ADAMTS 的特异性抑制剂或激活剂已成为研究关节病、血栓疾病及心血管病的新策略[1]。
ADAMTS is a class of zinc-dependent secreted metalloproteases that primarily participate in extracellular matrix (ECM) degradation and remodeling, blood coagulation regulation, and cardiovascular homeostasis. This family consists of 19 ADAMTS proteases and 7 ADAMTS-like proteins, each with distinct biological functions. Among them, ADAMTS1, 4, and 5 are responsible for proteoglycan degradation, ADAMTS2, 3, and 14 facilitate procollagen processing, ADAMTS13 regulates coagulation by cleaving von Willebrand factor (vWF), and ADAMTS7 and 12 influence vascular smooth muscle cell migration, contributing to atherosclerosis. Additionally, ADAMTS1 and ADAMTS8 function as tumor suppressors, inhibiting angiogenesis and thereby restricting tumor growth. Dysregulation of ADAMTS functions is associated with various diseases. For example, mutations in ADAMTS2 lead to Ehlers-Danlos syndrome (a connective tissue disorder with skin hyperelasticity) due to impaired collagen maturation; excessive ADAMTS5 activity disrupts proteoglycan homeostasis and exacerbates osteoarthritis; ADAMTS13 deficiency causes thrombotic thrombocytopenic purpura (TTP), resulting in abnormal blood clot formation. Additionally, ADAMTS7 promotes vascular remodeling, accelerating atherosclerosis progression. Therefore, selective inhibitors or activators targeting ADAMTS have emerged as potential therapeutic strategies for joint diseases, thrombotic disorders, and cardiovascular conditions[1].
© 2026 MolStrong. 保留所有权利。粤ICP备2023004355号
可通过CAS号进行批量搜索,一行一个CAS号